Certolizumab pegol reduces symptoms in patients with moderately to severely active Crohn's disease - Commentary

Research output: Contribution to journalComment/debate

Original languageEnglish (US)
Pages (from-to)32-33
Number of pages2
JournalEvidence-Based Gastroenterology
Volume9
Issue number2
DOIs
StatePublished - May 1 2008

ASJC Scopus subject areas

  • Gastroenterology

Cite this